Obio Technology Shanghai Corp

Obio Technology Shanghai Corp Current Assets

The Current Assets of Obio Technology Shanghai Corp (688238.SS) as of Oct 31, 2026 is 126.59 M CNY. In the previous year, Current Assets was 252.80 M CNY — a change of -49.93% (lower).

Current Assets

126.59 MCNY

YoY

-49.93%

Last updated:

Current Assets of Obio Technology Shanghai Corp is 2025 126.59 M CNY. Current Assets of Obio Technology Shanghai Corp was 2024 252.80 M CNY. It decreases by -49.93% lower compared to the previous year.

The Obio Technology Shanghai Corp Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
59.29 M CNY
Jan 1, 2019
55.98 M CNY
Jan 1, 2020
299.37 M CNY
Jan 1, 2021
149.66 M CNY
Jan 1, 2022
245.09 M CNY
Jan 1, 2023
356.16 M CNY
Jan 1, 2024
252.80 M CNY
Jan 1, 2025
126.59 M CNY
The Obio Technology Shanghai Corp Current Assets history
YEARCurrent AssetsYoY
126.59 MCNY-49.93%
252.80 MCNY-29.02%
356.16 MCNY+45.32%
245.09 MCNY+63.76%
149.66 MCNY-50.01%
299.37 MCNY+434.82%
55.98 MCNY-5.59%
59.29 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Obio Technology Shanghai Corp Stock analysis

What does Obio Technology Shanghai Corp do? Obio Technology Shanghai Corp Ltd provides biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO services. The company offers contract research organization (CRO) services including gene therapy vector development and gene function research for gene therapy basic research, as well as contract research and development production organization (CDMO) services for gene drug R&D, such as pharmaceutical research and clinical sample production. It serves European and American markets and the domestic market with its CRO and CDMO offerings. The firm generates revenue through CRO services like gene therapy vector development and gene function research, and CDMO services including pharmaceutical research and clinical sample production. Its primary clients are companies involved in gene therapy and gene drug development, focusing on the European and American markets and domestic segments. The company's services support the research and development phases of gene therapy and gene drug products. Obio Technology Shanghai Corp Ltd's business model centers on providing specialized research and production services for gene therapy and gene drug development. By offering both CRO and CDMO services, it addresses key needs in the gene therapy industry, particularly in vector development and clinical sample production, targeting pharmaceutical companies and research institutions in Europe, America, and China. Obio Technology Shanghai Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Obio Technology Shanghai Corp stock

Current Assets of Obio Technology Shanghai Corp is 126.59 M CNY in 2025.

Current Assets of Obio Technology Shanghai Corp changed from 252.80 M CNY to 126.59 M CNY, representing a -49.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Obio Technology Shanghai Corp since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Obio Technology Shanghai Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Obio Technology Shanghai Corp

All Key Metrics — Obio Technology Shanghai Corp